BCL2L1 and neoplasm: Similarly, in prostate and ovarian cancer cells siRNA-mediated Bcl-xL knockdown inhibited tumour cell proliferation and sensitised cells towards cisplatin and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), respectively (38,39).